INNOVATION

2009 ANNUAL REPORT

The Leukemia & Lymphoma Society
Fighting Blood Cancers
CURE LEUKEMIA, LYMPHOMA, HODGKIN’S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.

MISSION
In looking back on The Leukemia & Lymphoma Society’s (LLS) 60 years, there is one defining characteristic that shows up in everything we do: Innovation. It is evident in every area of our mission, from our research track record, through innovative patient services programs and in new legislative victories that address the needs of the blood cancer population. This year’s report will highlight some of the innovations that have helped patients with blood cancers live better, longer lives and show some of the survivors who have benefited from LLS innovations.

More than anything else, this 60th anniversary is a time when we are looking forward. The landscape in which we live and work is going through powerful changes and we grasp the need to adapt quickly, moving toward a culture that supports and nurtures fresh perspectives and solutions at every level of our organization, from the local chapter to the national board room.

We have created a legacy of innovation. Now, it’s time to re-commit, with new vigor and resolve, as we remember the words of the German poet and intellectual, Goethe: “Whatever you can do or dream you can, begin it. Boldness has a genius, power and magic in it.”

John E. Walter • President and CEO  
Steven L. Hooker • Chair
LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. Over our 60 years of existence, we have thrived on a spirit of innovation in all aspects of our mission. Our continuous support for the best research, wherever in the world it is being done, is a testament to innovation.
When LLS was founded in 1949, a diagnosis of leukemia, lymphoma or myeloma was almost always fatal. Today, thanks to innovative research funded in part by LLS, survival rates for some blood cancers have doubled, or even tripled. In fact, some blood cancer survival rates rose as much as four-fold from 1960 to 2005.

LLS-funded research programs include traditional grants to individual researchers and research teams as well as the more recent model of funding projects at companies and health organizations that will accelerate the advancement of our mission. These programs support discoveries that have led or contributed to new treatments and that have saved the lives of patients battling many types of cancer. Read about two such innovations below.

* **GLEEVEC®**

Ten years ago, the five-year survival rate for patients with chronic myelogenous leukemia (CML) was less than 50 percent. Then, an LLS-funded researcher, Brian Druker, MD, developed the targeted drug Gleevec® (approved 2001). Now, the survival rate for patients with newly diagnosed, chronic phase CML has nearly doubled, to 95 percent, and they enjoy a high quality of life. Gleevec is also FDA-approved for patients with a rare form of stomach cancer called GIST, and the drug is being tested for patients with many other kinds of malignancies.

* **THERAPY ACCELERATION PROGRAM**

Innovations in research have helped us become the third-largest generator of private support among all U.S. voluntary health organizations – behind only The American Cancer Society and The American Heart Association. This is truly phenomenal when you consider the “orphan status” of our diseases.

One such innovation that makes the future look even brighter for patients with blood cancers is a new program that will bring more treatments to more patients faster. Through our Therapy Acceleration Program, we are partnering with biotechnology companies to facilitate the rapid development of promising new therapies that might otherwise go undeveloped. The program is also helping to overcome a key barrier in getting patients into clinical trials by developing novel models that will bring those trials into communities where patients live. And the Therapy Acceleration Program is accelerating the development of new discoveries in its pipeline by funding applied research, paving the way for FDA approval.

“Our LLS chapter has been there for us, with support and information that has helped immensely. We’ve formed a Friends and Family Team for Light The Night Walk and it feels so rewarding to raise funds to help others who, like Layla, are bravely battling blood cancers.”

* ALECIA HEFTER
Layla’s Mom
INNOVATIONS IN PATIENT SERVICES

Nearly 913,000 people across the United States currently battle leukemia, lymphoma and myeloma. LLS offers a comprehensive array of services to guide blood cancer patients and their caregivers to make informed decisions, access the most current treatment and clinical trial options and provide support services so each patient may have the best possible outcome and quality of life. Last year alone, LLS made 4.9 million contacts with patients, caregivers and healthcare professionals.

* INFORMATION RESOURCE CENTER

Only LLS provides individualized information to patients and their caregivers about blood cancers, resources, treatments and other critical issues through our Information Resource Center.

* PEDIATRIC CANCERS

We have created and implemented an innovative program, The Trish Greene Back to School Program for Children with Cancer, to help smooth the way for children returning to school after cancer treatment, with education and tools for teachers and school personnel.

* FIRST CONNECTION

This novel peer-to-peer program, started in 1995, matches newly diagnosed patients and family members with trained volunteers who have been through similar cancer journeys, and arranges contact. The program is provided through LLS chapters in communities throughout the U.S. and Canada.

LAYLA HEFTER

In this photo, Layla was three and had successfully completed her first year of chemo to treat acute lymphocytic leukemia (ALL). In spite of all she’s gone through, she’s still smiling! She enjoys reading books with her mom, playing with her princess dolls and especially, visiting the animals at the zoo. These days, Layla is looking forward to her 2½ years of treatment to be over and, thanks to research, she should have a future with plenty of time for smiles.
“Since being diagnosed with myeloma, I’ve been glad to have the assistance of LLS. For one thing, research they helped fund resulted in Velcade®, one of the drugs I’m being treated with. For another, their financial assistance program has come in very handy during my illness. Thank goodness for LLS.”

+ MANUEL TAPIA

INNOVATIONS IN ADVOCACY

LLS has made vital contributions that advance our mission through advocacy at both state and national government levels. In past years, for example, we helped initiate the first blood cancer lobby day in Washington, D.C.; we have advocated for legislation to continue insurance coverage for standard-care costs when patients participate in clinical trials, with coverage now expanded to 28 states; championed the first legislation in the country to provide neuro-psychological testing for pediatric cancer survivors; helped establish the first blood cancer research program at the Department of Defense; and initiated a blood cancer patient education program funded through the Centers for Disease Control and Prevention.

INNOVATIONS IN FUNDRAISING

Our signature fundraising program, Team In Training® (TNT), is the world’s first and largest charity sports training program, raising nearly $1 billion for blood cancer research and patient support since its inception 21 years ago! Often imitated, but never equaled, TNT makes a major impact on the lives of people battling blood cancers.

LLS entered online search and fundraising early. These efforts have not only proven to be successful, but also have caught the attention of Google, which has been generous with its support and is currently writing a case history based on our experience.
LLS also has a virtual, remote, in-house center for telemarketing and customer support, improving customer service and creating cost savings.

LLS also found that strategic partnerships can have a meaningful impact on our revenue goals. Thanks to Scott Key, Team In Training Alumni and Senior Vice President of Marketing at Gap, Inc., LLS was included in Gap’s Give & Get program for the first time in the spring of 2009. The discount coupon promotion helped raise $600,000 for LLS due in large part to heavy viral promotion conducted online.

LOOKING AHEAD

Our goal is a future in which LLS has transformed the lives of people with blood cancer and the healthcare landscape that patients, families and caregivers navigate. LLS will continue to lead with innovation, embracing change to keep ahead of a world that’s changing fast.

As a cancer survivor recently acknowledged, “LLS was like finding a window to hope and knowledge.” This is a window that we promise will never be closed.
In 2009, LLS continued to make progress toward cures. The following pages provide updates on our mission areas and on the many programs that support them.

**RESEARCH HIGHLIGHTS**

LLS developed and utilizes an innovative system to support new therapies from discovery through testing and into clinical use to help blood cancer patients. Our research grant programs facilitate basic, translational and multi-disciplinary research; our Therapy Acceleration Program focuses on parts of the therapy development pipeline in which bottlenecks too often occur. We recently saw a wonderful example of the full strategy at work in the case of a new drug with great promise for the treatment of some patients with leukemia, lymphoma and even solid tumors.

In 2004, an LLS grant funded studies of Aaron Schimmer, MD, PhD, FRCPC, at the Ontario Cancer Institute. Dr. Schimmer’s investigation focused on a protein called XIAP that had been associated with resistance to chemotherapy among patients with acute myeloid leukemia (AML). He identified chemicals that inhibit this protein and confirmed that these targeted drugs could help kill AML cells.

In 2007, Dr. Schimmer used additional LLS funding to extend his earlier work into clinical studies of a particularly promising anti-XIAP drug (AEG35156). It was used in combination with chemotherapy in 51 AML patients and found safe and effective, producing remissions in nearly half of the patients for whom other therapies had failed.

LLS continues to help advance this promising new therapy through its Therapy Acceleration Program, supporting new trials of AEG35156. This time, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and two types of lymphomas are being enrolled in a Phase I study to determine the safety and optimal dose of this drug. A Phase II study will follow to measure the drug’s effectiveness at the highest safe dose.

The Therapy Acceleration Program also takes clinical trials to patients where they live. CLL and lymphoma patients now have access to AEG35156 trials at three community treatment centers, made possible by LLS’s groundbreaking partnership with the Cleveland Clinic Taussig Cancer Institute.

This story, which follows the development of a drug from basic to translational research and into clinical trials, past several points where its development might have stalled, demonstrates the importance of LLS’s continuum of support, and is an LLS innovation success story.
Aaron Schimmer
MD, PhD, FRCPC
Ontario Cancer Institute
PATIENT SERVICES

• LLS’s Information Resource Center (IRC), staffed by masters-level professionals responded to nearly 80,000 inquires this year helping patients navigate treatment, clinical trial options and support services.

• Over 3,200 clinical trial searches were conducted using the new IRC clinical trial search tool, Trial Check, created in partnership with the Coalition of Cancer Cooperative Groups.

• The LLS co-pay assistance program awarded over $19.2 million in support to patients to assist them with prescription drug co-pay and insurance premium obligations.

• Over 407,000 patients, caregivers and healthcare professionals attended national LLS Web cast and teleconference blood cancer education programs and over 56,000 attended community-based LLS chapter education programs.

• LLS chapters offered 516 family support groups across the U.S. and Canada, 7,000 First Connection matches occurred matching newly diagnosed patients with trained volunteers, and nearly 3,000 school personnel, healthcare professionals and parents attended the LLS education program “Welcome Back: Facilitating the School Experience for Childhood Cancer Survivors.”

LAURA WHITAKER

LAURA WAS DIAGNOSED WITH CLL IN 2000, AND SAYS SHE WAS, “A LITTLE LOST” UNTIL AN LLS PATIENT SERVICES MANAGER GAVE HER INFORMATION ON HER DISEASE AND TREATMENT OPTIONS, AND TOLD HER ABOUT CLINICAL TRIALS THAT HELPED GET HER CANCER INTO REMISSION. A SCHOOL LIBRARIAN, SHE ALSO GIVES BACK AS A VERY ACTIVE VOLUNTEER, PARTICIPANT AND FUNDRAISER FOR LLS. LAURA SAYS SHE LIVES WITH “ZEST AND GUSTO,” AND SURROUNDS HERSELF WITH POSITIVE PEOPLE.
**Advocacy**

- LLS volunteer advocates led coalition efforts that garnered passage of legislation in Colorado, Indiana, Oregon and Texas that ensures access and insurance coverage for patients in potentially life-saving clinical trials. This coverage is now required by 28 states and the District of Columbia.

- LLS spearheaded a patient coalition that resulted in enhanced blood cancer research at the Department of Defense in a newly focused $20 million peer-reviewed cancer program and a new bone marrow failure disease program.

- Teamed with other pediatric cancer groups, LLS secured passage of the Carolyn Pryce Walker Conquer Childhood Cancer Act (H.R. 1553), ensuring the expansion of pediatric cancer research, increased public awareness of treatments and the creation of a national childhood cancer registry.

- LLS launched a new and improved LLS Advocates Network communication and mobilization system which provided 45,000 blood cancer advocates with fresher, more timely and targeted information, and more opportunities to get involved and make their voices heard.
Fundraising

Team in Training
Last year, LLS launched its second, co-branded Team In Training event, the Nation’s Triathlon To Benefit The Leukemia & Lymphoma Society. In its inaugural season, TNT brought 700 participants to this sold-out event, raising $3 million to help find cures for blood cancers. In 2009, a third co-branded event, the Women’s Running Magazine Women’s Half Marathon To Benefit The Leukemia & Lymphoma Society was created, adding to LLS’s fast-growing co-branded events arena. This new half marathon will take place in November 2009, in scenic St. Petersburg, FL.

Light the Night Walk
This year, new emphasis was placed on developing strategies to recruit more businesses to form teams and provide sponsorship. These include identifying, recruiting and engaging volunteers who are active in their community and well connected to serve as the Corporate Walk Chair or on Executive Committees. These volunteers will bring their contacts to Corporate Recruitment Events, helping secure new corporate teams and sponsorship. Light The Night will also continually replenish volunteers by having existing leaders replace themselves when their term is up.
SCHOOL & YOUTH PROGRAMS
These innovative programs continue to engage students in communities across the country, resulting in participation in nearly a quarter of the nation’s schools. A new tactic this year, acknowledging individual classrooms with pennants to recognize their fundraising success, encouraged students to keep on fundraising. The coveted pennants – bronze, silver and gold – were awarded to classrooms who met different fundraising milestones.

MAN & WOMAN OF THE YEAR
This successful fundraising program continues its expansion into new geographies, attracting dynamic community leaders who commit themselves to raise funds to support lifesaving cancer research. The local Man & Woman of the Year titles are announced at festive gala celebrations and the top fundraisers nationwide earn the national titles. Local and national winners are congratulated in a full-page ad in USA Today.

DONOR DEVELOPMENT
Thanks to commitments from generous individuals, foundations, and organizations who recognize the importance of affirming the LLS mission, $23.4 million was contributed in FY 2009 for specific initiatives. Significant income from magnanimous individuals who remembered LLS in their estate plans was also realized during this period. These deferred gifts are increasingly important as LLS seeks to heighten its impact on blood cancer research and therapy acceleration.

Funds are supporting basic and translational studies, encouraging greater access to clinical trials, and fostering partnerships among academic institutions, medical centers, and companies to accelerate new therapies to market. Outreach to patients and their families has also been enhanced, enabling LLS to provide supportive and educational resources from the earliest days of diagnosis through their journey.

Recognizing the importance of keeping generous benefactors informed, the Giving Circle, new this year, provides special access to experts in blood cancer research and treatment.

2009 NATIONAL MAN OF THE YEAR
DAWSON GRIMSLEY
PRESIDENT & OWNER
DAVIS-MOORE AUTO GROUP
WICHITA, KS
REES NAYLOR
GIRL OF THE YEAR

2009 NATIONAL WOMAN OF THE YEAR
ARI JONES
MOMS FOR A CURE
FAIRFAX, VA
ALESSANDRO VALERI
BOY OF THE YEAR
RESEARCH GRANTS

SPECIALIZED CENTER OF RESEARCH

THE SPECIALIZED CENTER OF RESEARCH PROGRAM FUNDS MULTIDISCIPLINARY RESEARCH BY TEAMS OF LEADING-EDGE ACADEMIC INVESTIGATORS THAT HASTENS THE DISCOVERY AND DEVELOPMENT OF BETTER TREATMENTS FOR LEUKEMIA, LYMPHOMA AND MYELOMA PATIENTS. A CENTER IS COMPOSED OF AT LEAST THREE INDEPENDENT RESEARCH PROGRAMS THAT ARE INTEGRATED AND SUPPORTED BY SCIENTIFIC CORE LABORATORIES.

Jerry Adams, PhD
Walter & Eliza Hall Institute of Medical Research

Frederick Alt, PhD
Immune Disease Institute

Jon Aster, MD, PhD
Brigham & Women’s Hospital

Irwin Bernstein, MD
Children’s Hospital of Philadelphia

Ronald Levy, MD
Stanford University

Jonathan Licht, MD
Northwestern University School of Medicine

Scott Lowe, PhD
Cold Spring Harbor Laboratory

Beverly Mitchell, MD
University Health Network

Stephen Nimer, MD
Memorial Sloan-Kettering Cancer Center

Michael Thirman, MD
The University of Chicago

Cheryl Willman, MD
University of New Mexico

Linda Baughn, PhD
Albert Einstein College of Medicine

Michael Begley, PhD
Beth Israel Deaconess Medical Center

Mihac Benson, PhD
Harvard Medical School

Avinash Bhandoola, MD, PhD
University of Pennsylvania

Anja-Katrin Bielinsky, PhD
University of Minnesota, Twin Cities

Susan Biggins, PhD
Fred Hutchinson Cancer Research Center

Daniel Billadeau, PhD
Mayo Clinic and Foundation

Debabrata Biswas, PhD
Rockefeller University

Dale Bixby, MD, PhD
University of Michigan

Marie Bleakley, MD
Fred Hutchinson Cancer Research Center

Marzena Blonska, PhD
University of Texas MD Anderson Cancer Center

Michael Boddy, PhD
The Scripps Research Institute

Catherine Bollard, MD
Baylor College of Medicine

Niccolo Bollini, MD
Dana-Farber Cancer Institute

Tatiana Bondar, PhD
Yale University

Ivan Borrello, MD
Johns Hopkins University School of Medicine

Marina Boussquet, PhD
Whitehead Institute for Biomedical Research

Lihua Budde, MD, PhD
Fred Hutchinson Cancer Research Center

Gerd Bungartz, PhD
Massachusetts General Hospital

Laura Butitta, PhD
Fred Hutchinson Cancer Research Center

Kenneth Campellone, PhD
University of California, Berkeley

Julie Camnan, PhD
Ludwig Institute for Cancer Research

Kate Carroll, PhD
University of Michigan

Andrew Carter, PhD
University of California, San Francisco

Pedro Carvalho, PhD
Harvard Medical School

Lucio Castilla, PhD
University of Massachusetts Medical School

Asher Chanan-Khan, MD
Health Research Incorporated, Roswell Park Cancer Institute Division

Yi-Bin Chen, MD
Massachusetts General Hospital

Tao Cheng, MD
University of Pittsburgh

Vivian Choi, PhD
Immune Disease Institute

Yoonsu Choi, PhD
University of Texas MD Anderson Cancer Center

Stella Chou, MD
Children’s Hospital of Philadelphia

Eric Chow, MD
Fred Hutchinson Cancer Research Center

Wen-Ming Chu, MD, PhD
Brown University

Sergei Chukov, PhD
University of Michigan

Elaine Chung, PhD
University of Pennsylvania

Karlene Cimprich, PhD
Stanford University

Maria Ciofani, PhD
New York University School of Medicine

Pasquale Cireore, PhD
Yale University

1. Dr. John H. Buswell is funded in part by the Breed–Adams Foundation.
2. Dr. John Byrd is funded in part by Elaine Smith, Douglas A. and Phyllis Smith and Michael and Jacqueline Thomas.
3. Dr. Ricardo Dalla-Favera is funded in part by the Joseph S. and Diane H. Steinberg Charitable Trust.
4. Dr. Brian Druker is funded in part by Imagine a Cure for Leukemia.
7. Dr. Scott Lowe is funded in part by The Ataschlu Foundation/Reichman Memorial.
8. Dr. Beverly Mitchell is funded in part by The Joseph C. Sandilippo Memorial Fund
19 Dr. Anthony Letai is fully funded by Millennium: The Takeda Oncology Company.

20 Dr. Weei-Chin Lin is funded in part by the Susan B. Komen for the Cure - Mott Webb Trust and Walter and Beth Grant.

21 Dr. Ari Melnick is funded in part by Quest Diagnostics, Inc.

22 Dr. Geeta Narlikar is funded in part by Walter and Beth Grant.

23 Dr. Robert Orlowski is funded in part by the Douglas Kroll Research Foundation.

24 Dr. Alexander Perl is funded in part by the Douglas Kroll Research Foundation.

25 Dr. Danilo Perrotti is funded in part by Mark and Christine Kraemer and Charles and Lynda Kraemer.
Dr. Wei-Jong Shia, a Stephen Birnbaum Scholar, 24
Dr. Linda Resar is funded in part by the Cora and John H. Davis Foundation.
Andrey Revyakin, PhD
University of California at Berkeley. 25
Dr. Erika Shor is funded in part by the Greater Milwaukee Foundation’s Elsa Schonemann Medical Research Fund.
Tannishtha Reya, PhD
University of California at Berkeley. 26
Dr. Warren Shlomchik is fully funded by The Stephen Birnbaum and John H. Davis Foundation.
Laurence Ehrlich, PhD
University of Michigan. 27
Dr. John Welch is fully funded by the Dallas Saint Valentine’s Luncheon and Fashion Show.
Edward Rogers, PhD
Rockefeller University. 28
Jianchang Yang, MD, PhD
Nevada Cancer Institute. 29
Theodora Ross, MD, PhD
University of Toronto. 30
Dr. Ming Xu is fully funded by Northwestern Mutual Life Foundation, Inc.
Robin Ricke, PhD
Stanford University. 31
Dr. Demin Wang is funded in part by Mayo Clinic and Foundation.
Monideepa Roy, PhD
University of Michigan. 32
Dr. Wei-Jong Shia is funded in part by the Dallas Saint Valentine’s Luncheon and Fashion Show.
Davide Robbiani, MD, PhD
 Rockefeller University.
Smita Shankar, PhD *
University of California, San Francisco.
Sonia Sharma, PhD
Immune Disease Institute.
Craig Vander Kooi, PhD
University of Kentucky.
David Sharp, PhD
Albert Einstein College of Medicine.
Lidia Vasilevva, PhD
Oxford University.
Wei-jong Shia, PhD 21
University of California, San Diego.
Shobha Vasudevan, PhD
Massachusetts General Hospital.
Warren Shlomchik, MD 26
Yale University.
Zhou Songyang, PhD
Baylor College of Medicine.
Peter Sicsinski, MD, PhD
Dana-Farber Cancer Institute.
Rachael Siegel, PhD
Columbia University.
Zhao Staton, PhD
Harvard University School of Public Health.
Milan Stojevic, PhD
University of California, San Francisco.
Erika Shor, PhD 23
University of Wisconsin at Madison.
Travis Stracker, PhD
Institute for Research in Biomedicine.
Mitchell Weiss, MD, PhD
Children’s Hospital of Philadelphia.
Matthew Stout, MD, PhD
Yale University.
Wojciech Swat, PhD
Washington University in St. Louis.
Demin Wang, PhD 21
Blood Research Institute.
Gergely Szakacs, MD, PhD
University of North Carolina at Chapel Hill.
Ivan Topolpavlovic, MD, PhD
McGill University.
Giovanni Tonon, MD, PhD
Fondazione Centro S. Raffaele del Monte Tabor.
Emily Troemel, PhD
University of Texas MD Anderson Cancer Center.
Jennifer Trowbridge, PhD 29
Dana-Farber Cancer Institute.
William Wierda, MD, PhD
University of Chicago.
Hsin-yue Tsai, PhD
University of Massachusetts Medical School.
Ning Wu, PhD
University of Oxford.
Yu Zha, PhD*
Memorial Sloan-Kettering Cancer Center.
Neil Shah, MD, PhD *
University of California, San Francisco.
Vasiliki Tsakalakides, PhD
Massachusetts Institute of Technology.
Tao Wu, PhD
Harvard Medical School.
Katharine Ullman, PhD
University of Utah.
Joseph Villadangos, PhD
Walter & Eliza Hall Institute of Medical Research.
Dan Vogl, MD
University of Pennsylvania.
Carl Walkley, PhD
St. Vincent's Institute of Medical Research.
Johannes Walter, PhD
Harvard Medical School.
Roland Walter, MD, PhD
Fred Hutchinson Cancer Research Center.
Demin Wang, PhD
University of North Carolina at Chapel Hill.
Michael Weiss, MD, PhD
Children’s Hospital of Philadelphia.
John Welch, MD, PhD*
Washington University in St. Louis.
Ginger Wernig, MD
Brigham & Women’s Hospital.
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center.
Sarah Wignall, PhD
Stanford University.
Petter Woll, PhD *
University of Oxford.
Zhengjian Zhang, PhD
University of California, Berkeley.
Jianrong Zhang, MD, PhD
Immune Disease Institute.
Yungfeng Zhang, PhD
Duke University Medical Center.
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center.
Sarah Wignall, PhD
Stanford University.
Petter Woll, PhD *
University of Oxford.
Zhengjian Zhang, PhD
University of California, Berkeley.
Jianrong Zhang, MD, PhD
Immune Disease Institute.
Yungfeng Zhang, PhD
Duke University Medical Center.
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center.
Sarah Wignall, PhD
Stanford University.
Petter Woll, PhD *
University of Oxford.
Zhengjian Zhang, PhD
University of California, Berkeley.
Jianrong Zhang, MD, PhD
Immune Disease Institute.
Yungfeng Zhang, PhD
Duke University Medical Center.
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center.
Sarah Wignall, PhD
Stanford University.
Petter Woll, PhD *
University of Oxford.
Zhengjian Zhang, PhD
University of California, Berkeley.
Jianrong Zhang, MD, PhD
Immune Disease Institute.
Yungfeng Zhang, PhD
Duke University Medical Center.
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center.
Sarah Wignall, PhD
Stanford University.
Petter Woll, PhD *
University of Oxford.
Zhengjian Zhang, PhD
University of California, Berkeley.
Jianrong Zhang, MD, PhD
Immune Disease Institute.
Yungfeng Zhang, PhD
Duke University Medical Center.
William Wierda, MD, PhD
University of Texas MD Anderson Cancer Center.
Sarah Wignall, PhD
Stanford University.
Petter Woll, PhD *
University of Oxford.
Zhengjian Zhang, PhD
University of California, Berkeley.
Jianrong Zhang, MD, PhD
Immune Disease Institute.
Yungfeng Zhang, PhD
Duke University Medical Center.
**RESEARCH GRANTS CONTINUED**

**TRANSLATIONAL RESEARCH PROGRAM**

**THE TRANSLATIONAL RESEARCH PROGRAM SUPPORTS OUTSTANDING INVESTIGATIONS DEEMED BY OUR EXPERT ADVISORS MOST LIKELY TO TRANSLATE BASIC BIOMEDICAL DISCOVERIES INTO NEW, SAFE AND EFFECTIVE TREATMENTS, ULTIMATELY PROLONGING AND ENHANCING PATIENTS’ LIVES.**

Albert Baldwin, PhD
University of North Carolina at Chapel Hill

Julio Barreto, MD
University of Miami School of Medicine

Pamela Becker, MD, PhD
University of Washington

Linda Bendall, PhD
University of Sydney

Smita Bhatia, MD
City of Hope National Medical Center

Helen Blau, PhD
Stanford University

Bruce Blazar, MD
University of Minnesota, Twin Cities

Katherine Borden, PhD
Université de Montréal

Carl Borrebaeck, PhD
Lund University

John Byrd, MD
Ohio State University

Nicola Camp, PhD
University of Utah

Asher Chanan-Khan, MD
Health Research Incorporated, Roswell Park Cancer Institute Division

Preet Chaudhary, MD, PhD
University of Pittsburgh

Wei Chen, MD, PhD
University of Minnesota, Twin Cities

Selina Chen-Kiang, PhD
Well Medical College of Cornell University

Jason Chesney, MD, PhD
University of Louisville Brown Cancer Center

Kent Christopherson, PhD
Rush University Medical Center

Curt L. Chin, MD
University of Maryland School of Medicine

Michael Cleary, MD
Stanford University

Christopher Cogle, MD
University of Florida

Wendy Cozen, DO
University of Southern California

Alan D’Andrea, MD
Dana-Farber Cancer Institute

George Daley, MD, PhD
Brigham & Women’s Hospital

Chi Dang, MD, PhD
Johns Hopkins University School of Medicine

James DeGregori, PhD
University of Colorado at Denver

Gerald Denis, PhD
Trustees of Boston University

Maurizio Di Liberto, PhD
Well Medical College of Cornell University

Gianpietro Dotti, MD
Baylor College of Medicine

Ming-Qing Du, MD, PhD
The University of Cambridge

Elizabeth Eklund, MD
Northwestern University School of Medicine

Martin Fernandez-Zapico, MD
Mayo Clinic and Foundation

Adolfo Ferrando, MD, PhD
Columbia University

James Ferrara, MD
University of Michigan

Christopher Flowers, MD
Emory University

Richard Ford, MD, PhD
University of Texas M.D. Anderson Cancer Center

Arthur Frankel, M.D.
Scott and White Memorial Hospital

Yarsha Gandhi, PhD
University of Texas M.D. Anderson Cancer Center

Guillermo Garcia-Manero, MD
University of Texas M.D. Anderson Cancer Center

Celine Gelinas, PhD
UMDNJ – Robert Wood Johnson Medical School

Alan M. Gewirtz, MD
University of Pennsylvania School of Medicine

Jolanta Grembecka, PhD
University of Michigan

Steven Gore, MD
Johns Hopkins University School of Medicine

Monica Guzman, PhD
University of Rochester

Lori Hazlehurst, PhD
H. Lee Moffitt Cancer Center & Research Institute

Laurence Hurley, PhD, DSC
University of Arizona

Craig Jordan, PhD
University of Rochester

Scott Kaufmann, MD, PhD
Mayo Clinic and Foundation

Tomas Kirchhoff, PhD
Memorial Sloan-Kettering Cancer Center

Susan Knox, MD, PhD
Stanford University

Donald Kufe, MD
Dana-Farber Cancer Institute

Wen-Hwa Lee, PhD
University of California at Irvine

Hsiou-Chi Liou, PhD
Well Medical College of Cornell University

Mignon Loh, MD
University of California, San Francisco

Sagar Lonia, MD
Emory University

Lawrence Lum, MD, DSC
Wayne State University

Nadim Mahmut, MD, PhD
University of Illinois – Chicago

Ari Melnick, MD
Well Medical College of Cornell University

David Miklos, MD, PhD
Stanford University

Ramzi Mohammad, PhD
Wayne State University

Jeffrey Muldrem, MD
University of Texas M.D. Anderson Cancer Center

Sherie Morrison, PhD
University of California, Los Angeles

Markus Muschen, MD
Children’s Hospital Los Angeles

Owen O’Connor, MD, PhD
Columbia University

Vivian Oehler, MD
Fred Hutchinson Cancer Research Center

Craig Okada, MD, PhD
Portland Veterans Affairs Medical Center

Robert Orlowski, MD, PhD
University of Texas M.D. Anderson Cancer Center

Angel Pellicer, MD, PhD
New York University School of Medicine

Leonidas Platanias, MD, PhD
Northwestern University School of Medicine

Feyruz Rassool, PhD
University of Maryland, Baltimore

Yosef Refaeli, PhD
National Jewish Medical Research Center

Susan Rheingold, MD
The Children’s Hospital of Philadelphia

Alain Rook, MD
University of Pennsylvania

Joseph Rosenblatt, MD
University of Miami

Janet Rowley, MD
The University of Chicago

Kathleen Sakamoto, MD
University of California, Los Angeles

Felipe Samaniego, MD
University of Texas M.D. Anderson Cancer Center

Barbara Savoldo, MD, PhD
Baylor College of Medicine

Aaron Schimmer, MD, PhD
University Health Network

Motomu Shimao, MD, PhD
Immune Disease Institute

11 Dr. John Byrd is funded in part by Imagine a Cure for Leukemia.
12 Dr. Nicola Camp is funded in part by Nicholas and Denni Ferrara, Leukemia Research Foundation of Delaware.
13 Dr. Jason Chesney is funded in part by The Mansbach Foundation.
14 Dr. Alan D’Andrea is funded in part by The Robert H. Lyon Leukemia Foundation.
15 Dr. Monica Guzman is funded in part by Robert and Jufanna Beh.
16 Dr. Craig Jordan is funded in part by Robert and Jufanna Beh and the Douglas Kroll Research Foundation.
17 Dr. Susan Knox is funded in part by The Valley Foundation.
18 Dr. Markus Muschen is funded in part by the California Community Foundation.
19 Dr. Yosef Refaeli is funded in part by Big B’s New York Pizza Dek.
20 Dr. Kathleen Sakamoto is funded in part by Parents Against Leukemia and Mike Sheln.
21 Dr. Benjamin Tycko is funded in part by the Douglas Kroll Research Foundation.
22 Dr. David Williams is funded in part by The Marge & Charles J. Schott Foundation and The Horren R. Downey Fund of the Greater Cincinnati Foundation.
Acute Lymphocytic Leukemia Research Portfolio

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio

Chronic Lymphocytic Leukemia Research Portfolio

Chronic Myelogenous Leukemia Research Portfolio

Hodgkin Lymphoma Research Portfolio

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio

Aggressive Non-Hodgkin Lymphoma Research Portfolio

Indolent Non-Hodgkin Lymphoma Research Portfolio

Pediatric Research Portfolio

Therapy Acceleration Program

Waldenstrom Macroglobulinemia Initiative

Waldenstrom Scientific Research Symposium

* Newly awarded or renewed grants in fiscal year 2010
MEDICAL AND SCIENTIFIC ADVISORS

CHAIR
Armand Keating, MD
Princess Margaret Hospital

VICE CHAIR
Margaret Shipp, MD
Dana-Farber Cancer Institute

Irwin Bernstein, MD
Fred Hutchinson Cancer Research Center

David Bodine, PhD
National Institutes of Health

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University

Curt I. Civin, MD
University of Maryland School of Medicine

Jorge Cortes, MD
The University of Texas, M.D. Anderson Cancer Center

Claude Geoff Davis, PhD
Angelica Therapeutics, Inc.

James H. Davis, PhD, JD
Human Genome Sciences, Inc.

Brian Druker, MD
Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute

David Frantze, JD
Stinson, Morrison, Heckler, LLP

Alan M. Gewirtz, MD
University of Pennsylvania, School of Medicine

D. Gary Gilliland, MD, PhD
Merck & Co., Inc.

James Griffin, MD
Dana-Farber Cancer Institute

Charles F. Inglefield
American Technical Coatings, Inc.

Judith Karp, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Michael W. Long, PhD
Velcura Therapeutics, Inc.

W. Stratford May, Jr., MD, PhD
University of Florida, Shands Cancer Center

Beverly S. Mitchell, MD
Stanford University

Warren S. Pear, MD, PhD
The University of Pennsylvania, Abramson Family Cancer Research Institute

Kanti R. Rai, MD
Long Island Jewish Medical Center

Steven T. Rosen, MD
Northwestern University, Robert H. Lurie Comprehensive Cancer Center

Naomi Rosenberg, PhD
Tufts University School of Medicine

Nancy Speck, PhD
University of Pennsylvania, School of Medicine

Guido Tricot, MD, PhD
University of Utah, School of Medicine

Cheryl L. Willman, MD
University of New Mexico Cancer Research and Treatment Center

PROFESSIONAL EDUCATION SUBCOMMITTEE

CHAIR
Irwin Bernstein, MD
Fred Hutchinson Cancer Research Center

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University

Brian Druker, MD
Howard Hughes Medical Institute, Oregon Health & Science University Cancer Institute

James Griffin, MD
Dana-Farber Cancer Institute

Judith Karp, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Michael W. Long, PhD
Velcura Therapeutics, Inc.

Beverly S. Mitchell, MD
Stanford University Cancer Research Center

Margaret Shipp, MD
Dana-Farber Cancer Institute

ENDOWMENT FUNDS

The Bill Beattie Memorial Endowment Fund (Alberta)

Mary & Robert Bronstein Memorial Fund

The Virginia Major Brooks Memorial Endowment Fund
de Villiers Endowment Fund

Thomas M. Ford Memorial Fund

GlaxoSmithKline Foundation and GlaxoSmithKline, Inc. Research Fund

Jim Jacobs Leukemia Research Fund

The Rachel Kudish Fund

Jane Elissa/Charlotte Meyers Endowment Fund

The Rae Endowment Fund (Ontario)

Vrushali Ranadive Fellowship Fund

Reich Endowment Fund

The UFCW (Canada) Endowment Fund
## DONORS

**The Below Listing is Made up of Individuals, Foundations and Corporations That Generously Supported LLS’s Mission During This Fiscal Year.**

### $1,000,000 and Above
- Burlington Coat Factory
- Celgene Corporation
- Centers for Disease Control and Prevention*
- The Simon C. Fireman Charitable Foundation*
- Genentech, Inc.
- Millennium: The Takeda Oncology Company
- Novartis Pharmaceuticals, Inc.
- The Coleman Foundation
- United Food & Commercial Workers Union (Canada)
- United Food & Commercial Workers Union (UFCW)

### $500,000 – $999,999
- The Harriett R. Downey Fund of the Greater Cincinnati Foundation
- Elbit Systems of America, LLC
- Eli Lilly and Company
- Deborah Flanagan
- Dworken & Bernstein Co. LPA
- Gilead Sciences
- The Jeff Gordon Foundation
- The Hearn Foundation
- Hyundai Hope on Wheels
- Imagine a Cure for Leukemia
- Industrial Alliance Insurance and Financial Services Inc.
- International Waldenstrom’s Macroglobulinemia Foundation*
- Jack’s Mannequin
- Virginia Sheldon Jerome Foundation
- Pamela B. Katten Memorial Leukemia Research Foundation
- Sydney and Isabel Kemper
- Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation*
- Labors’ International Union of North America
- Rush Limbaugh
- Timothy and Christine Lindenfels*er
- Lord, Abbott & Co. LLC
- The Manischewitz Foundation
- Clyde Smith McGregor
- Mercedes-Benz USA, LLC
- Nike
- Novartis Pharma Canada Inc.
- The Olive Garden Italian Restaurant
- P.F. Chang’s China Bistro
- The Olive Garden Italian Restaurant
- P.F. Chang’s China Bistro
- Phoenix Partners Group
- PowerBar
- Province of British Columbia
- Quest Diagnostics, Inc.
- Regence BlueCross BlueShield
- Runner’s World
- Jeff and Pat Sachs*
- The Marge & Charles J. Schott Foundation*
- Schwinn
- Seagate Technology
- Siemens
- Stater Bros. Markets
- Joseph S. and Diane H. Steinberg Charitable Trust*
- Michael and Jacqueline Thomas
- Vistar Corporation
- Wachovia
- WCCO AM 680 The Fan
- Anonymous (1)

### $100,000 – $499,999
- AIG
- Air Products
- Atlas Therapeutics, Inc.
- American Electric Power
- Austaco, Inc.
- Robert and JoAnna Behl*
- Big Steaks Management LLC
- Peter Bing*
- The Stephen Birnbaum Foundation*
- BMHC
- Peter Burg Memorial Research Fund
- Citrix Systems
- The Coleman Foundation
- Community Health Charities of New England
- Dallas Saint Valentine’s Luncheon and Fashion Show
- DiaAmerica
- The Harriett R. Downey Fund of the Greater Cincinnati Foundation
- Eliit Systems of America, LLC
- Eli Lilly and Company
- Deborah Flanagan*
- Dworken & Bernstein Co. LPA
- The Jeff Gordon Foundation
- The Hearn Foundation
- Hyundai Hope on Wheels
- Imagine a Cure for Leukemia
- Industrial Alliance Insurance and Financial Services Inc.
- International Waldenstrom’s Macroglobulinemia Foundation*
- Jack’s Mannequin
- Virginia Sheldon Jerome Foundation
- Pamela B. Katten Memorial Leukemia Research Foundation
- Sydney and Isabel Kemper
- Steven and Michele Kirsch Fund, an advised fund of the Silicon Valley Community Foundation*
- Labors’ International Union of North America
- Rush Limbaugh
- Timothy and Christine Lindenfelser*
- Lord, Abbott & Co. LLC
- The Manischewitz Foundation
- Clyde Smith McGregor
- Mercedes-Benz USA, LLC
- Nike
- Novartis Pharma Canada Inc.
- The Olive Garden Italian Restaurant
- P.F. Chang’s China Bistro
- The Olive Garden Italian Restaurant
- P.F. Chang’s China Bistro
- Phoenix Partners Group
- PowerBar
- Province of British Columbia
- Quest Diagnostics, Inc.
- Regence BlueCross BlueShield
- Runner’s World
- Jeff and Pat Sachs*
- The Marge & Charles J. Schott Foundation*
- Schwinn
- Seagate Technology
- Siemens
- Stater Bros. Markets
- Joseph S. and Diane H. Steinberg Charitable Trust*
- Michael and Jacqueline Thomas
- Vistar Corporation
- Wachovia
- WCCO AM 680 The Fan
- Anonymous (2)

### $50,000 – $99,999
- AIG Science & Technology
- American Airlines
- AMERICAN SYSTEMS
- Ham Ansley Memorial Research Fund
- Apache Corporation
- AutoTrader.com
- BAE Systems
- BDO Seidman LLP
- Brian and Lisa Bee – Spin 4 the Cure
- Hildegarde D. Becher Foundation, Inc.
- The John and Frances Beck Family Foundation*
- Beers + Cutler
- Biogen Idec, Inc.
- Booz Allen Hamilton
- Peter Brock*
- California Community Foundation
- CapitalSource
- Carlson Family Foundation*
- Cisco Systems, Inc.
- Community Health Charities of Minnesota
- Cricket Communications
- Dana West Yacht Club
- Cora and John H. Davis Foundation
- Lawrence J. and Florence A. DeGeorge Charitable Trust
- Deutsche Bank
- Eisai, Inc.
- Future Tech Enterprise, Inc.
- General Dynamics Information Technology
- Walter and Beth Grant*
- Hargrove
- Leon W. (Pete) Harman
- Ed Heitz Memorial Research Fund
- Leon W. (Pete) Harman
- Lighthouse Investment Partners LLC
- Troy Stoike
- Ed Heitz Memorial Research Fund
- Lemonade Foundation
- Linus Foundation
- Los Angeles Rams
- Mobil
- Morgan Stanley
- NetApp
- Northrop Grumman Mission Systems
- Parents Against Leukemia
- PNNMA
- Ping T. Tai Foundation, Inc.
- Jonathan Plutzik & Lesley Goldwasser Family Foundation
- PricewaterhouseCoopers LLP
- Raley’s Employee Giving Campaign
- Remillard Family Foundation*
- Carroll Rogers
- Richard and Nancy Rogers
- Dale and Esther Roulston
- San Diego Yacht Club
- The Victor E. and Caroline E. Schutte Foundation – Trust E
- Sigma Alpha Epsilon Fraternity, University of Georgia
- Elaine Smith
- John W. & Effie E. Speas Memorial Trust
- Target Corporation
- Team Friends of Heroes – Honoring Pediatric Heroes
- Rick and Susan Theer – Cure Kids Cancer Golf
- Paul Touw
- Toyota
- Transamerica Life Canada
- The Valley Foundation
- Waddel & Reed
- WCCO Radio
- Susan Matt Webb Trust*
- Wells Fargo
- Wilson Farms, Inc.
- Wyleth Pharmaceuticals
- Anonymous (1)

### $10,000 – $49,999
- 7-Eleven
- Abbott Oncology
- Accenture
- AIG Highstar
- ACS
- Ann Adams
- Howell and Madeline Adams, Jr.
- In memory of Madeline Adams
- The Adams Family
- ADJ Sheetmetal

* denotes multi-year commitment
Aegon Media North America
Aetna
Aetna Foundation
John W. Alden Trust
Allen & Company, Inc.
Alliance Data
Alliance Holdings, Inc.
Allianz Life Insurance Company of North America
Alston Foundation
The Altshul Foundation/Reichman Memorial
AlwynCosgrove.com, Inc.
American General Life & Accident
American Health Insurance Plans
America’s Charities
Amerimade Technology, Inc.
AmeriPath, Inc.
Ameris Construction
Amerigen, Inc.
Helen Anbinder
Stephen and Madeline Anbinder
John Andrews
Mark Andrews
Angler Construction
Jennifer Anthony
ARAMARK
Robert Arnott
The Arthur Foundation
Assent, LLC
Association of Indian Physicians of Northern Ohio
AstraZeneca
Astros In Action Foundation
Avilaots Corporation
Jerry and Kay Baer
Baker Botts, LLP
Tim Banazek
Banca Popular
Bank of America
The Bank of New York Mellon
Bank of Tokyo – Mitsubishi, UFJ
Barbour Griffith & Rogers
Barclays Bank Delaware
Barefoot Wines
Matthew Barger
Mike and Susie Barnett
The Barrett Family Foundation
Barroway Topaz Kessler Metzler & Check, LLP
BASF Corporation
Bass Pro Shops
Carlos Batista Foundation
Bay 101
Bayer, Inc.
BD Biosciences
Bedford Falls Foundation
Beerman Foundation
Bell Family Foundation
Bell Microproducts
Robert Bells
Sheila J. Belsky
The Belvedere Cove Foundation
Shelley Bergman
The Bill Bernbach Foundation
Jay Bernstein
Bertrand Berry Foundation
Bert Smith & Co.
Berwind Corporation
Bert Against Cancer
Big Bill’s New York Pizza Deli
BIO
Alexandra Mays Brimbaum
Black & Decker
The Blackie Foundation
The Blackstone Charitable Foundation
BlueCross BlueShield
Edward & Susan Blumenfeld Foundation
Boca Java, Inc.
Boca Raton Community Hospital
Boeing Employees Community Fund
Nadine Bognar
The Bohlen Family Foundation
Herman & Emmie Bolden Foundation
Bomgarder Learjet
Boston Foundation
Bower Engineering Corporation
Helen Brach Foundation
Donald and Marianne Bradley
Braman Motorcars
Steve and Linda Brannon
Brasscraft-Navo
Aaron Braun and Joan DeHovitz
Brayton Purcell
Breakthrough Management Group International
Brecher Design Group
The Breeden-Adams Foundation
Colt Brennan
Brewers of Indiana Guild, Inc.
The Broad Foundation
Brocade
Broward Health
Brown & Gould
Eileen Burg
Burns & McDonnell Foundation
Burson-Marsteller
Tim Byrnes
CA Corporate Headquarters
Cadence Design Systems
Campbell & Company
Canada Life Assurance Company
Samuel C. Cantor Charitable Trust
Capital Federal
Capital File Magazine
Capital Source
Capstone Advisory Group, LLC
Carter BloodCare
Don and Linda Carter
Thomas and Agnes Carvel Foundation
Casino Arizona
Celebreve Learning Centers
Center For Executive Development
Centric Bank
CGI
CGI Federal
CH2M-HILL
Charles Schwab Corporation
David Chase
The Rhoda and David Chase Family Foundation, Inc.
Chiaramonte Construction Company
Chicago Cubs Charities
The Children’s Mercy Hospital
Chill Media, Inc.
Chittenden
Chrysler-Jeep-Dodge Advisory Association
Crina
Clark Construction Group, LLC
The Clark Foundation
The Classic Catering People
Clear Channel
Clerys, Gittlens, Steen & Hamilton
Cleveland Indians Baseball Company
CN
The Cornelius J. Coakley Family Foundation
Coca-Cola North America
Alexandra Cohen
The Steven A. and Alexandra M. Cohen Foundation
Columns Resource Group Foundation, Inc.
Combined Health Agencies
Commerce Bank
Community Foundation of Greater Atlanta
Community Health Charities of Georgia
Community Health Charities of Illinois
Community Health Charities of Iowa
Community Health Charities of New York
Community Health Charities of Virginia
Community Health Charities of Wisconsin
Comstock Homebuilding
Contemporary Electrical Services, Inc.
Cook Children’s Medical Center
Chris Cook
Diane Cook-Tench
Coones Memorial 5K Pumpkin Run-Walk
CoreMedical Group
Alvern M. Carmell Foundation
Corporate Synergies
Melissa Tsigars Corsa
Costco Wholesale
Tim and Maura Costello
The Meredith A. Cowden Foundation
Rick and Debby Cox*
Coyle-Varland Insurance Agency, Inc.
Crawl For Cancer
Louise Creason
Creative & Productions Resources, Inc.
Credit Suisse
The Cromar Foundation
Grove Horvath
Cub Foods and Proctor & Gamble
Richard Cullen
Cumberland Packing Corporation
CXTech
Cypress Semiconductor
Robert Dahl
Dah-Kunt For The Cure, LLC
Larry Dale
Timothy Daly
Danaher Corporation
Danford Foundation
John Dapper
DARCAR
The Darvish Family
Kelvin Davis and Rachel Brewster
Davis-Moore Auto Group
Donald and Leona Davis
DC Rental
M.C. Dean
Erica Deitko
Deloitte
John DeRosa
Robert and Renee DeVinck
The Devine Family Foundation
Robert Dimson
DLA Piper
Dominick’s
Dominion Mechanical
Downriver Junior Football League
DRM Construction
DRA Properties, LC – Dennis Albaugh
Drieuhaus Capital Management, LLC
Duffy Mechanical Corp.
Ed and Anna Dunlap
Dunn Family Foundation
Lakefront Communications, Inc.
Marie Lamfrom Charitable Foundation
LandRover Dallas
Chris Lantman
Christen Lapina
Latham & Watkins
Cliff and Kristen Lee
Kelli Leffingwell Bonacci and The Tony Leffingwell Foundation
Legacy Bank
Lehman Brothers
Lehman Motors
Jeffrey Leiserowitz
John and Muffin Lemak
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LLS Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Malosti Family Ltd. Partnership
The Employees of Maple Lodge Farms
Austin Marrs
Marsh Risk & Insurance Services
Martin, Harding & Mazzotti
Kenneth Massaroni
Betsy Matoff
Maxim Integrated Products
Maxygen
Mayo Foundation
McArthurGlen UK Ltd.
John McCready
The June & Cecil McDole Charitable Fund
Casey McGill
Sean and Erin McGould
McGuire Patmore Foundation
McKee Nelson, LLP
McKenna, Long & Aldridge
McKinsey & Company, Inc.
McKee Nelson, LLP
McGuire Patmore Foundation
Sean and Erin McGould
Casey McGlynn
The June & Cecil McDole Charitable Fund
John McCreadie
Mayo Foundation
Maxygen
Maxim Integrated Products
Betty Matoff
Kenneth Massaroni
Martin Liberman
Ken and Barbara Lieberman
Steven Lieblich
LifeSource
Linebarger Goggan Blair & Sampson
List Innovative Solutions
LSL Researchers Team
Lockheed Martin
Danna Loren
The Lotz Family Foundation
LSI Corporation
Lucidity Consulting Group
Lundbeck, Inc.
Lukas Lundin
Jane MacElree
MacKenzie Partners, Inc.
Brian and Kayla Roughton
Fred and Bernice Rowan
The Royal Bank of Scotland
Royal Marine Insurance Group
RR Donnelley
RR EEF
Paul & Joan Rubschlager Foundation
Ruby’s Diner
Runners for Life
George Rush
George B. Rush Law Corporation
Safeway, Inc.
Sailing World Magazine
Sallie Mae, Inc.
Loren Salsbery
Sam’s Club Foundation
The San Francisco Foundation
SanDisk
Sidney, Milton & Leoma Simon Community Foundation
Siemens Enterprise Communications, Inc.
Siemens Energy & Automation, Inc.
Siemens Healthineers
Sigma Phi Gamma International
Silicon Valley Community Foundation
Simon’s Family Foundation
The Sidney, Milton & Leoma Simon Foundation
Robin Singh
Phil and Sally Smart
Douglas A. and Phyllis Smith
Smith Productions
Barry and Meredith Snader
Kevin Sneader
Sobeys’ Distribution Centre
Nicholas and Suzanne Sopkin
Southeast Nebraska Hematology & Oncology
Southland Industries
SouthWest Bank
The Spagenberg Family Foundation
Mark and Carol Spisak
Sports Worx
Sprint Nextel
St. Joseph’s Candler
St. Luke’s Mountain States Tumor Institute
St. Vincent de Paul Foundation, Inc.
Oliver Stangl
The Doug Steele Family
Doug Steele Golf Fore Life Tournament
Dr. Peter and Sandra Stern
Sterne, Kessler, Goldstein & Fox, PLLC
John Stewart
Stinson Morrison Hecke, LLP
Sun Capital Partners
SunTrust Bank
Suzuki
Swanson Group Ltd.
SureTec
Sunesis Pharmaceuticals, Inc.
Style with Substance
Bill Stuckey
Synergy
Symaneci
The Taft Foundation
J.T. Tai & Co. Foundation
Chris Tarbell
Sean and Natalie Tarbell
Targeting Lymphoma Shoot
TBD Foundation
TDS Metrocom
Team Todd
TeamFootWorks
Technology Concepts & Design, Inc.
TeleVerde
TELLUS Vancouver Community Board
The Mike & Mary Terry Family Foundation
Texas Instruments, Inc./Raj Gupta Memorial Fund
Texas Oncology, PA
The M Group/TBD
Gillis and Billie Thomas
Thompson, Habib & Derivson, Inc.
Edgar A. Thomson Foundation, Inc.
TXK Companies, Inc.
Touchstone Energy Cooperatives
Toyota
Toyoda Motor Sales
Toyota of Owatonna
Traino’s Wine & Spirits
Transamerica Retirement Services
Travelport
Terri Trevillian
TRIB Total Media
Tropicana Casino and Resort
Truland Service Corporation
Mr. and Mrs. Robert Tischy
Tube City IMS
Margaret B. Turner
Turner Interiors
Turner Special Projects
Jack A. Turpin
U.S. Bankruptcy Foundation
UBS Investment Bank
United States Steel Corporation
United Way of Metropolitan Atlanta, Inc.
University of Pittsburgh Medical Center
University of Michigan Medical Center
In memory of Bill Van Burkleo
Venable LLP
Verizon
Vion Pharmaceuticals
Virginia Mason Medical Center
Vitol, Inc.
Volkswagen Group of America
Wachovia Securities
Waddell & Reed Kansas City Marathon
Gloria Somerville Wagner
Stephanie Walker Fund
Mrs. Dwane Wallace
Wal-Mart Foundation
Walton Construction
Washington Business Journal
Washington Gas
Washington Post Media & Cars.com
Wal-Mart Foundation
Walton Construction
Washington Post Media & Cars.com
Waste Management
The Waterford Foundation
The Watkins Family
Watkins, Meeghan, Drury & Company, LLC
Watson Wyatt Worldwide
Anna Webb
Wechsler & Marsico Associates
Martin Weinberg
Wendy’s of Michigan
West Marine
Virginia Westlake
The Frederick and Margaret L. Weyerhaeuser Foundation
Wheeler Family Charitable Foundation
Virginia Whetstone
Charlie and Shelley Whetzel
John Whitaker
White & Case, LLP
White Castle
David White
The Whitney Foundation
WLNE Networks
Williams & Connolly, LLP
John Eddie Williams
Fred Wilpon
Winston Partners Group, LLC
Wipeout Leukemia Forever Foundation, Inc.
WVSB-TV
Richard and Kaye Weltman
Woodbine Entertainment
The Woodlands Operating Company
Woodmen of the World
Rose City Camp #77
WTOP Radio
Emily Wylly
In honor of Gustavo Yepes, Jr.
YRC Worldwide
Ziokowski Patent Solutions Group
ZIOPHARM Oncology, Inc.
In memory of Ted Zuckerma
Joseph Zvesper
Anonymous (15)

* denotes multi-year commitment
The legacy circle honors those who name Lls in their wills, or as beneficiaries of a trust, retirement account or insurance policy or enter into a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Donaldene Moore
Scott Murray
Dorothy M. Murray
Amitha Newsam
Tara Pachmayer
Anthony Pasko
Pat’s Team
Hayden Pedra
Sarah Jon Porreca
Dan Perillo
Quest Diagnostics, Inc.
The Riders of the Storm
Mary Jo Robinson & Team Fighting 4 A Cure
Dr. David Roer
Carroll Rogers
Dale and Esther Roulston
Lindsey Scott
Seagate Technology
Joe M. Sergi
Bill Shen
Bill Smith
Stater Bros. Markets
Paxanne Tava
Team W.O.W.
TUAC
Vistar
Wachovia
Tom Wensinger
Travis Willard and Honoree Woodside
Nancy Wilson
Elaina Wolpe
Eric Yutz
Anonymous
Norman Abel*  
Colleen Bailey
Leahbelle Balbach*
Louise Barrows*
Doris Bayes*
Steven and Nancy Bender
Steven and Lynn Berardo
Andrew and Edith Berto*
Edward Blaskey*
Ronald Bogus*
Keith Brantley
William and Kathleen Burawski
Mary Lou Busardo*
Coy and Lucille Byerly*
Josip Cajic
*  
Yvonne Cartier*
Lois Chamberlain
Lucille Coffey*
Lauren Cohen*
Beatrice Cuneo*
Keith Culhane
Beatrice Jackson
Mary Lou Busardo*
Coy and Lucille Byerly*
Josip Cajic
*  
Ella Mae Fenn*
Christina Ferraioli*
Simon and Norma Fireman
Cesar Gapite*
John Gallo*
Nick Gonte*
Ruth Granat*
Eilen Greene*
Linda Gunther*
Julia Gurganus*
Ann Harrell*
Judith Helfant*
William Hissey*
Howard Hveem*
Beatrice Jackson*
Caroll Johnson*
John Kaufmann*
Richard Kelbaugh
Steven Kleinman*
William Krueger*
Jonathan Lehto*  
Melvin Lintz*
Yvonne Lucassen*
Irene Mollo*
Lois Mayer*
Lamar McCarty*
Stewart and Vera McDonald*
Kate McPadden*
Ina Meyers*
Chuck and Glenda Michael
Robert Cleo Mitchell*
Peter Moonal*
Barbara Morse*
Matthew and Henrietta Norris*
Mildred O’Hearn*
Stephen O’Shee
Mary and Andrew Passafaro*
Susa Pax*
Richard and Sarah Pietrafesa
John Procopio*
Rade Rakovic*
Maurice Roseman*
Frank Sandler
Norbert Sarnow*
Leonard Scharffenberger*
William Hill Sewell
Irene Sidun
Katherine Sinkovitz
Robert Smutny*
Fred and Jacqueline Spencer*
Michael Starr
Jacqueline Stem
Albert and Angelina Strauss*
Bruce and Anne Swartz*
Ann Swoboda*
Lorraine Walz*
Kerry Weinberg*
Catherine Jean Wickenden Mooney*
Genevieve Wilson*
Doris Woychik*
Barbara Young
Ruth Zyskowski
Anonymous (3)

† National Man & Woman of the Year
* Deceased
The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated statement of financial position of The Leukemia & Lymphoma Society, Inc. (the Society) as of June 30, 2009, and the related consolidated statements of activities, functional expenses, and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Society's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. The prior year summarized comparative information has been derived from the Society's 2008 consolidated financial statements and, in our report dated October 20, 2008, we expressed an unqualified opinion on those statements.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2009, and the changes in its net assets and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.

KPMG LLP

September 15, 2009
## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

THE LEUKEMIA & LYMPHOMA SOCIETY, INC.  •  JUNE 30, 2009

(WITH COMPARATIVE AMOUNTS AT JUNE 30, 2008)  (IN THOUSANDS)

<table>
<thead>
<tr>
<th>Assets</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$28,196</td>
<td>$36,180</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>4,314</td>
<td>4,807</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>75</td>
<td>1,360</td>
</tr>
<tr>
<td>Legacies and contributions receivable (note 2)</td>
<td>22,752</td>
<td>7,167</td>
</tr>
<tr>
<td>Investments (note 3)</td>
<td>161,623</td>
<td>162,978</td>
</tr>
<tr>
<td>Fixed assets, less accumulated depreciation and amortization of $12,544 and $12,069</td>
<td>4,616</td>
<td>5,148</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$221,576</strong></td>
<td><strong>$217,640</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Net Assets</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$14,682</td>
<td>$20,700</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>15,479</td>
<td>17,174</td>
</tr>
<tr>
<td>Grants payable (notes 4 and 5)</td>
<td>85,768</td>
<td>81,670</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>115,929</strong></td>
<td><strong>119,544</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets (note 9):</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>78,551</td>
<td>83,085</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>23,596</td>
<td>11,932</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,500</td>
<td>3,079</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>105,647</strong></td>
<td><strong>98,096</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total liabilities and net assets</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>$221,576</strong></td>
<td><strong>$217,640</strong></td>
</tr>
</tbody>
</table>

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.
## CONSOLIDATED STATEMENT OF ACTIVITIES

THE LEUKEMIA & LYMPHOMA SOCIETY, INC. • YEAR ENDED JUNE 30, 2009

(WITH SUMMARIZED TOTALS FOR THE YEAR ENDED JUNE 30, 2008) (IN THOUSANDS)

### Revenue

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$260,876</td>
<td>$30,526</td>
<td>$119</td>
<td>$291,521</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(39,077)</td>
<td></td>
<td></td>
<td>(39,077)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>221,799</td>
<td>30,526</td>
<td>119</td>
<td>252,444</td>
</tr>
<tr>
<td>Legacies</td>
<td>9,198</td>
<td>17,261</td>
<td></td>
<td>26,459</td>
</tr>
<tr>
<td>Donated services (note 1)</td>
<td>6,829</td>
<td></td>
<td></td>
<td>6,829</td>
</tr>
<tr>
<td>Net interest and dividend income (note 3)</td>
<td>6,375</td>
<td>83</td>
<td>9</td>
<td>6,467</td>
</tr>
<tr>
<td>Net (decrease) increase in fair value of investments</td>
<td>(7,159)</td>
<td>(161)</td>
<td>5</td>
<td>(7,315)</td>
</tr>
<tr>
<td>Grant refunds</td>
<td>2,768</td>
<td></td>
<td></td>
<td>2,768</td>
</tr>
<tr>
<td>Redesignation of net assets</td>
<td>(288)</td>
<td></td>
<td></td>
<td>(288)</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>36,045</td>
<td>(36,045)</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td><strong>275,567</strong></td>
<td><strong>11,664</strong></td>
<td><strong>421</strong></td>
<td><strong>287,652</strong></td>
</tr>
</tbody>
</table>

### Expenses (note 10)

#### Program Services:

- Research: 69,786 – – 69,786 76,979
- Patient and community service: 93,448 – – 93,448 77,886
- Public health education: 41,331 – – 41,331 42,094
- Professional education: 8,497 – – 8,497 8,433

Total program services: 213,062 – – 213,062 205,192

#### Supporting Services:

- Management and general: 23,259 – – 23,259 24,942
- Fund raising: 43,132 – – 43,132 46,052

Total supporting services: 66,391 – – 66,391 70,994

Total expenses: 279,453 – – 279,453 276,186

Change in net assets before foreign currency translation adjustment: (3,886) 11,664 421 8,199 861

Foreign currency translation adjustment: (648) – – (648) 37

Change in net assets: (4,534) 11,664 421 7,551 898

### Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>Beginning of year</th>
<th>End of year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>83,085</td>
<td>78,551</td>
</tr>
<tr>
<td></td>
<td>11,932</td>
<td>23,596</td>
</tr>
<tr>
<td></td>
<td>3,079</td>
<td>5,500</td>
</tr>
<tr>
<td></td>
<td>98,096</td>
<td>105,647</td>
</tr>
<tr>
<td></td>
<td>97,198</td>
<td>98,096</td>
</tr>
</tbody>
</table>

SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.
## Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. Year ended June 30, 2009 (With comparative totals for the year ended June 30, 2008) (in thousands)

### Program Services

<table>
<thead>
<tr>
<th>Research</th>
<th>Patient and Community Service</th>
<th>Public Health Education</th>
<th>Professional Education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants</td>
<td>$63,542</td>
<td>–</td>
<td>–</td>
<td>$63,542</td>
</tr>
<tr>
<td>Therapy acceleration program (note 6)</td>
<td>2,294</td>
<td>–</td>
<td>–</td>
<td>2,294</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>–</td>
<td>7,437</td>
<td>–</td>
<td>7,437</td>
</tr>
<tr>
<td>Co-pay assistance (note 5)</td>
<td>–</td>
<td>19,211</td>
<td>–</td>
<td>19,211</td>
</tr>
<tr>
<td>Donated services</td>
<td>856</td>
<td>5,973</td>
<td>–</td>
<td>6,829</td>
</tr>
<tr>
<td>Salaries</td>
<td>1,649</td>
<td>31,111</td>
<td>16,449</td>
<td>45,156</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 7)</td>
<td>222</td>
<td>7,840</td>
<td>4,856</td>
<td>12,538</td>
</tr>
<tr>
<td>Occupancy (note 8)</td>
<td>36</td>
<td>3,546</td>
<td>2,385</td>
<td>6,484</td>
</tr>
<tr>
<td>Insurance</td>
<td>10</td>
<td>230</td>
<td>162</td>
<td>414</td>
</tr>
<tr>
<td>Telephone</td>
<td>38</td>
<td>2,421</td>
<td>1,075</td>
<td>1,511</td>
</tr>
<tr>
<td>Travel</td>
<td>56</td>
<td>883</td>
<td>571</td>
<td>1,635</td>
</tr>
<tr>
<td>Printing and supplies</td>
<td>172</td>
<td>2,672</td>
<td>5,641</td>
<td>8,585</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>19</td>
<td>841</td>
<td>566</td>
<td>1,454</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>71</td>
<td>1,224</td>
<td>3,522</td>
<td>4,768</td>
</tr>
<tr>
<td>Meetings</td>
<td>485</td>
<td>1,877</td>
<td>814</td>
<td>3,577</td>
</tr>
<tr>
<td>Professional fees</td>
<td>304</td>
<td>6,540</td>
<td>4,240</td>
<td>11,324</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>8</td>
<td>996</td>
<td>622</td>
<td>1,614</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>24</td>
<td>639</td>
<td>428</td>
<td>1,306</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$69,786</strong></td>
<td><strong>$93,448</strong></td>
<td><strong>$41,331</strong></td>
<td><strong>$213,565</strong></td>
</tr>
</tbody>
</table>

### Supporting Services

<table>
<thead>
<tr>
<th>Management and General</th>
<th>Fundraising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awards and grants</td>
<td>$63,542</td>
<td>$69,134</td>
</tr>
<tr>
<td>Therapy acceleration program (note 6)</td>
<td>–</td>
<td>3,941</td>
</tr>
<tr>
<td>Financial aid to patients</td>
<td>–</td>
<td>7,437</td>
</tr>
<tr>
<td>Co-pay assistance (note 5)</td>
<td>–</td>
<td>19,211</td>
</tr>
<tr>
<td>Donated services</td>
<td>856</td>
<td>5,973</td>
</tr>
<tr>
<td>Salaries</td>
<td>1,649</td>
<td>31,111</td>
</tr>
<tr>
<td>Employee benefits and taxes (note 7)</td>
<td>222</td>
<td>7,840</td>
</tr>
<tr>
<td>Occupancy (note 8)</td>
<td>36</td>
<td>3,546</td>
</tr>
<tr>
<td>Insurance</td>
<td>10</td>
<td>230</td>
</tr>
<tr>
<td>Telephone</td>
<td>38</td>
<td>2,421</td>
</tr>
<tr>
<td>Travel</td>
<td>56</td>
<td>883</td>
</tr>
<tr>
<td>Printing and supplies</td>
<td>172</td>
<td>2,672</td>
</tr>
<tr>
<td>Equipment rentals and maintenance</td>
<td>19</td>
<td>841</td>
</tr>
<tr>
<td>Postage and shipping</td>
<td>71</td>
<td>1,224</td>
</tr>
<tr>
<td>Meetings</td>
<td>485</td>
<td>1,877</td>
</tr>
<tr>
<td>Professional fees</td>
<td>304</td>
<td>6,540</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>8</td>
<td>996</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>24</td>
<td>639</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$213,565</strong></td>
<td><strong>$276,186</strong></td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>25.0%</td>
</tr>
<tr>
<td>Patient and Community Service</td>
<td>33.4%</td>
</tr>
<tr>
<td>Public Health Education</td>
<td>14.8%</td>
</tr>
<tr>
<td>Professional Education</td>
<td>3.0%</td>
</tr>
<tr>
<td><strong>TOTAL PROGRAM SERVICES</strong></td>
<td><strong>76.2%</strong></td>
</tr>
<tr>
<td>Management and General</td>
<td>8.3%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>15.5%</td>
</tr>
<tr>
<td><strong>TOTAL SUPPORTING SERVICES</strong></td>
<td><strong>23.8%</strong></td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
### CONSOLIDATED STATEMENT OF CASH FLOWS

**THE LEUKEMIA & LYMPHOMA SOCIETY, INC. • YEAR ENDED JUNE 30, 2009**  
(WITH COMPARATIVE AMOUNTS FOR THE YEAR ENDED JUNE 30, 2008) (IN THOUSANDS)

<table>
<thead>
<tr>
<th></th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$ 7,551</td>
<td>$ 898</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjustments to reconcile the change in net assets to net cash (used in) provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net decrease in fair value of investments</td>
<td>7,315</td>
<td>4,839</td>
</tr>
<tr>
<td>Permanently restricted revenue collected</td>
<td>(119)</td>
<td>(142)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>1,717</td>
<td>1,825</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,285</td>
<td>326</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
<td>(15,585)</td>
<td>(2,846)</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>493</td>
<td>(96)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(6,018)</td>
<td>1,540</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(1,695)</td>
<td>1,916</td>
</tr>
<tr>
<td>Grants payable</td>
<td>4,098</td>
<td>4,425</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Net cash (used in) provided by operating activities</strong></td>
<td>(958)</td>
<td>12,685</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of fixed assets</td>
<td>(1,185)</td>
<td>(2,317)</td>
</tr>
<tr>
<td>Purchases of investments</td>
<td>(186,225)</td>
<td>(200,376)</td>
</tr>
<tr>
<td>Sales of investments</td>
<td>180,265</td>
<td>178,276</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(7,145)</td>
<td>(24,417)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cash flows from financing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permanently restricted contributions collected</td>
<td>119</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Net cash provided by financing activities</strong></td>
<td>119</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net decrease in cash and cash equivalents</td>
<td>(7,984)</td>
<td>(11,590)</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>36,180</td>
<td>47,770</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at end of year</strong></td>
<td>$28,196</td>
<td>$36,180</td>
</tr>
</tbody>
</table>

*SEE ACCOMPANYING NOTES TO CONSOLIDATED FINANCIAL STATEMENTS.*
I. Organization and Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (the "Society") is an international not-for-profit health agency dedicated to seeking the cause and cure of leukemia, lymphoma, Hodgkin’s disease, and myeloma and improving the quality of life of patients and their families. The Society’s principal activities include: awarding research grants; facilitating psychosocial support groups; providing financial aid to patients; answering phone requests for blood cancer information made to the Society's Information Resource Center; and disseminating educational information about blood cancers in the form of publications, internet sites, conference calls, and symposia sponsorship for both the medical community and the general public.

Tax-Exempt Status
The Society qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since the Society is publicly-supported, contributions to the Society qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is therefore not subject to income taxes if certain disbursement requirements are met.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Society which encompasses the Home Office of the Society and its sixty chapters in the United States, LLSC and the Society’s not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Inc. and The Leukemia & Lymphoma Society Research Foundation. All significant inter-company and intra-Society accounts and transactions have been eliminated in consolidation.

Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires the Society’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Risks and Uncertainties
The Society invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the statement of financial position.

Summarized Financial Information
The consolidated financial statements are presented with 2008 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2008 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with the Society’s 2008 consolidated financial statements from which the summarized information was derived. Certain reclassifications have been made to the 2008 comparative information to conform to the current year presentation.

Subsequent Events
The Society evaluated subsequent events after the statement of position date of June 30, 2009 through September 15, 2009, which was the date the financial statements were issued, and concluded that no additional disclosures are required.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to the Society, funds that have similar characteristics have been classified into three net asset categories as follows:

- **Unrestricted net assets**: Consist of funds that are fully available, at the discretion of the Society’s Board of Directors, for the Society to utilize in any of its programs or supporting services.
- **Temporarily restricted net assets**: Consist of funds that are restricted by donors for a specific time period or purpose.
- **Permanently restricted net assets**: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity and that only the income be used. Income earned on these funds may be unrestricted or temporarily restricted, depending upon the donor-imposed restrictions.

Foreign Currency Transactions and Translation
The consolidated financial statements are prepared in accordance with SFAS No. 52, Foreign Currency Translation. The Canadian operation uses the Canadian dollar as the functional currency. Accordingly, the currency impact of the translation of the statement of financial position of the Canadian operation to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Fair Value Measurements
Effective July 1, 2008, the Society adopted SFAS No. 157, Fair Value Measurements. SFAS No. 157 defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.

The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy under SFAS No. 157 are as follows:

- **Level 1**: Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Society has the ability to access at the measurement date.
- **Level 2**: Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
- **Level 3**: Inputs that are unobservable.

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Effective June 30, 2009, the Society elected to apply the concepts of proposed FASB Staff Position (FSP) No. 157-g (FSP 157-g), Estimating the Fair Value of Investments in Investment Companies That Have Calculated Net Asset Value per Share in Accordance with the AICPA Audit and Accounting Guide, Investment Companies. As a practical expedient, FSP 157-g permits an investor to estimate the fair value of an investment within the scope of FSP 157-g using the net asset value of the fund without future adjustment.

Contributions and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met.

Deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

Donated Services
The Society has determined that certain of the donated services it receives meet the criteria for recognition in the financial statements. Specifically, the donated services of family support group facilitators and research grant reviewers in the amount of $6,829,000 have been valued and are reported as both revenue and expense.
3. Investments

The following is a summary of investments at June 30, 2009 and 2008 (in thousands):

<table>
<thead>
<tr>
<th>Investment Type</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash equivalents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corporate notes and bonds</td>
<td>62,628</td>
<td>65,884</td>
</tr>
<tr>
<td>Common stocks and mutuals</td>
<td>29,411</td>
<td>25,184</td>
</tr>
<tr>
<td>Government obligations</td>
<td>49,788</td>
<td>50,738</td>
</tr>
<tr>
<td>Other</td>
<td>25,310</td>
<td>18,303</td>
</tr>
<tr>
<td>Total</td>
<td>$168,651</td>
<td>$161,623</td>
</tr>
</tbody>
</table>

Other investments at June 30, 2009 and 2008 consist principally of limited partnerships, the underlying holdings of which are principally marketable securities. Investment expenses of $568,000 and $416,000 have been netted against interest and dividend income for the years ended June 30, 2009 and 2008, respectively. The unrealized losses were $5,923,000 and $8,869,000 for the years ended June 30, 2009 and 2008, respectively.

All investments at June 30, 2009 are comprised of Level 1 assets except for $16,303,000 of other investments which are Level 3 assets.

The following table presents a reconciliation for all Level 3 assets measured at fair value as of June 30, 2009 (in thousands):

<table>
<thead>
<tr>
<th>Level 3 Assets</th>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at July 1, 2008</td>
<td>$19,334</td>
<td></td>
</tr>
<tr>
<td>Purchases</td>
<td>2,000</td>
<td></td>
</tr>
<tr>
<td>Investment expense</td>
<td>(103)</td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>332</td>
<td></td>
</tr>
<tr>
<td>Net decrease in fair value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>of investments</td>
<td>(5,260)</td>
<td></td>
</tr>
<tr>
<td>Balance at June 30, 2009</td>
<td>$16,303</td>
<td></td>
</tr>
</tbody>
</table>

4. Awards and Grants

Awards and grants for research are recognized as expense in the year approved by the Society’s Board of Directors. Multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of the Society’s Board of Directors. In addition to unconditional grants payable of $85,768,000 at June 30, 2009, the Society has grant commitments of $74,730,000 that are conditioned upon future events and, accordingly, are not recorded.

5. Co-Pay Assistance Program

The Co-Pay Assistance program offers assistance to patients in meeting their co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Approximately $7,448,000 is included in the grants payable balance for amounts awarded but unpaid at June 30, 2009.

6. Therapy Acceleration Program (“TAP”)

TAP is the Society’s strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new-drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of the Society’s Board of Directors. The Society has contract commitments of $7,190,000 at June 30, 2009 that are conditioned upon future events and, accordingly, are not recorded.
7. Pension Plan
The Society has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee’s salary and years of service. Expense under this plan aggregated $4,105,000 and $3,780,000 for the years ended June 30, 2009 and 2008, respectively.

The Society has a 457(b) Deferred Compensation Plan (the “457 Plan”), for its executive staff. The 457 Plan is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plan approximated $170,000 and $134,000 for the years ended June 30, 2009 and 2008, respectively. The assets and liabilities of the 457 Plan are included in investments and accounts payable in the accompanying consolidated statement of financial position and amounted to approximately $437,000 and $314,000 at June 30, 2009 and 2008, respectively.

8. Lease Commitments
The leases for premises which the Society’s Home Office and chapters occupy expire on various dates through May 31, 2018 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses and utilities. The Home Office lease expires in March 2016. The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>Thereafter</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7,243</td>
<td>5,897</td>
<td>4,806</td>
<td>3,100</td>
<td>2,167</td>
<td>3,812</td>
<td>27,025</td>
</tr>
</tbody>
</table>

9. Temporarily and Permanently Restricted Net Assets
Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2009 and 2008 (in thousands):

<table>
<thead>
<tr>
<th>2009</th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time restrictions</td>
<td>$16,566</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>Research</td>
<td>2,241</td>
<td>2,917</td>
<td>2,913</td>
</tr>
<tr>
<td>Patient service</td>
<td>4,658</td>
<td>420</td>
<td>8,972</td>
</tr>
<tr>
<td>Other</td>
<td>131</td>
<td>163</td>
<td>47</td>
</tr>
<tr>
<td>Total</td>
<td>$23,596</td>
<td>$3,500</td>
<td>$11,932</td>
</tr>
</tbody>
</table>

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2009 (in thousands):

<table>
<thead>
<tr>
<th>Endowment net assets at July 1</th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment income</td>
<td>43</td>
<td>76</td>
<td>9</td>
<td>128</td>
</tr>
<tr>
<td>Net (depreciation) appreciation</td>
<td>(710)</td>
<td>(161)</td>
<td>5</td>
<td>(866)</td>
</tr>
<tr>
<td>Contributions</td>
<td>-</td>
<td>-</td>
<td>119</td>
<td>119</td>
</tr>
<tr>
<td>Net assets released</td>
<td>153</td>
<td>(153)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Redesignation of net assets</td>
<td>(288)</td>
<td>-</td>
<td>288</td>
<td>-</td>
</tr>
<tr>
<td>Endowment net assets at June 30</td>
<td>$1,396</td>
<td>$397</td>
<td>$3,500</td>
<td>$5,293</td>
</tr>
</tbody>
</table>

The Society has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to protect the original value of the gift. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with the Society’s overall investment strategy.

10. Joint Costs Allocation
For the years ended June 30, 2009 and 2008, the Society incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th>2009</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$12,834</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>$1,013</td>
</tr>
<tr>
<td>Public health education</td>
<td>$10,188</td>
</tr>
<tr>
<td>Total</td>
<td>$24,035</td>
</tr>
</tbody>
</table>
NATIONAL LEADERS

CHAIRMAN OF THE BOARD
Steven L. Hooker
The Regence Group
Portland, OR

VICE CHAIR FOR MEDICAL AND SCIENTIFIC AFFAIRS
Armand Keating, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

VICE CHAIR FOR FIELD RELATIONS
Paul J. Cienki
Honeywell
Morristown, NJ

VICE CHAIR FOR PATIENT SERVICES
Marie Lauria, MSW
Chapel Hill, NC

VICE CHAIR FOR RESOURCE DEVELOPMENT
Margaret H. Anderson
Anderson, Bryant, Lasky & Winslow, PSC
Louisville, KY

SECRETARY/TREASURER
Thomas F. Hunter
Stimulys Performance Marketing
Chesterfield, MO

BOARD OF DIRECTORS
James A. Beck
Helfen-Tilton, Inc.
Butler, PA

Alexandra Mayes Birnbaum
Pearltime Communications, Inc.
New York, NY

Robert A. “Spider” Cantley
Twain Harte, CA

Scott Carroll
Jackson Lewis
Cincinnati, OH

Michael Copley
San Diego, CA

Jorge Cortes, MD
The University of Texas
M.D. Anderson Cancer Center
Houston, TX

Claude Geoffrey Davis
San Mateo, CA

James H. Davis, PhD, JD
Human Genome Sciences, Inc.
Rockville, MD

Timothy Durst
Baker Botts, LLP
Dallas, TX

Thomas L. Fitzpatrick
Saint Gobain Corporation
Worcester, MA

David Frantz, JD
Stinson, Morrison, Hecker, LLP
Kansas City, MO

Paul N. Frimmer
Irel & Manella, LLP
Los Angeles, CA

Alan M. Gewirtz, MD
University of Pennsylvania
School of Medicine
Philadelphia, PA

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Charles F. Inglefield
American Technical Coatings, Inc.
Cleveland, OH

John M. Kamin
Foster, Swift, Collins & Smith, PC
Farmington Hills, MI

Steven Lilly
NRUFC
Hermont, VA

Michael W. Long, PhD
Velcura Therapeutics, Inc.
Ann Arbor, MI

W. Stratford May, Jr., MD, PhD
University of Florida
Shands Cancer Center
Gainesville, FL

James McKinnis
Rapp Collins Worldwide
El Segundo, CA

Rodman N. Myers
Honigman Miller Schwartz and Cohn
Detroit, MI

Naomi Rosenberg, PhD
Tufts University School of Medicine
Boston, MA

Kevin R. Ryan
Citron Cooperman & Company, LLP
Philadelphia, PA

Norbert J. Sieber
NJG Consultants
Miami, FL

Jay L. Silver
Baylor College of Medicine
Sugar Land, TX

Mary Simmonds, MD
New Cumberland, PA

Thomas R. Snyder
Nashville Bank and Trust
Nashville, TN

William M. Ward, Jr.
Presbyterian Manors of Mid-America
Wichita, KS

Louise Warner
Chagrin Falls, OH

Kathryn West, RN, MSN, OCN
Avery
Thousand Oaks, CA

Michele Wong
Synergyx International Corporation
Gold River, CA


SENIOR STAFF

PRESIDENT AND CHIEF EXECUTIVE OFFICER
John E. Walter

CHIEF SCIENTIFIC OFFICER
RESEARCH & SCIENTIFIC PROGRAMS
Louis DeGennaro, PhD

CHIEF MEDICAL OFFICER
RESEARCH & MEDICAL PROGRAMS
Barton Kamen, MD, PhD

CHIEF MARKETING & REVENUE OFFICER
Nancy Klein

CHIEF FINANCIAL OFFICER
Jimmy Nangle

SENIOR VICE PRESIDENT
CHIEF INFORMATION OFFICER
Jeff Como

SENIOR VICE PRESIDENT
PUBLIC POLICY
George Dahlman

SENIOR VICE PRESIDENT
PATIENT SERVICES
Hildy Dillon

SENIOR VICE PRESIDENT
FIELD DEVELOPMENT
George Omiros

SENIOR VICE PRESIDENT
CHAPTER GROWTH
David Timko

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA

CHIEF EXECUTIVE OFFICER
Rudy Putns

GENERAL MANAGER OPERATIONS
Nancy Allen
# Chapter Offices

## Alphabetical by State

<table>
<thead>
<tr>
<th>State</th>
<th>Chapter Name</th>
<th>Address</th>
<th>Phone Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alabama</td>
<td>Alabama Gulf Coast Chapter</td>
<td>100 Chase Park South, Suite 220, Birmingham, AL 35244</td>
<td>205.989.0098</td>
</tr>
<tr>
<td>Arizona</td>
<td>Desert Mountain States Chapter</td>
<td>3877 North 7th Street, Suite 300, Phoenix, AZ 85014</td>
<td>602.567.7600</td>
</tr>
<tr>
<td>California</td>
<td>Central California Chapter</td>
<td>470 East Hermen-Side, Suite 102, Fresno, CA 93720-2929</td>
<td>559.435.1482</td>
</tr>
<tr>
<td></td>
<td>Greater Los Angeles Chapter</td>
<td>6033 West Century Boulevard, Suite 300, Los Angeles, CA 90045</td>
<td>310.342.5800</td>
</tr>
<tr>
<td></td>
<td>Greater Sacramento Area Chapter</td>
<td>2143 Hurley Way, Sacramento, CA 95825</td>
<td>916.929.4720</td>
</tr>
<tr>
<td></td>
<td>Greater San Francisco Bay Area Chapter</td>
<td>1390 Market Street, Suite 1200, San Francisco, CA 94102-5306</td>
<td>415.625.1100</td>
</tr>
<tr>
<td></td>
<td>Orange County Inland Empire Chapter</td>
<td>2020 East First Street, Suite 120, Santa Ana, CA 92605</td>
<td>714.481.5600</td>
</tr>
<tr>
<td></td>
<td>San Diego/Hawaiian Chapter</td>
<td>9150 Chatspave Drive, Suite 100, San Diego, CA 92123</td>
<td>858.277.1800</td>
</tr>
<tr>
<td></td>
<td>Silicon Valley &amp; Monterey Bay Area Chapter</td>
<td>675 North First Street, Suite 1100, San Jose, CA 95112-5156</td>
<td>408.490.2666</td>
</tr>
<tr>
<td>Colorado</td>
<td>Rocky Mountain Chapter</td>
<td>5332 West Dartmouth Avenue, Suite 400, Denver, CO 80227</td>
<td>303.984.2110</td>
</tr>
<tr>
<td>Connecticut</td>
<td>Connecticut Chapter</td>
<td>372 Danbury Road, Suite 200, Wilton, CT 06897</td>
<td>203.665.1400</td>
</tr>
<tr>
<td>Delaware</td>
<td>Delaware Chapter</td>
<td>100 West 10th Street, Suite 209, Wilmington, DE 19801</td>
<td>302.661.7300</td>
</tr>
<tr>
<td>Florida</td>
<td>Central Florida Chapter</td>
<td>3319 Magazine Boulevard, Suite 101, Orlando, FL 32803</td>
<td>407.898.0733</td>
</tr>
<tr>
<td></td>
<td>Northern Florida Chapter</td>
<td>7077 Booneal Road, Suite 610, Jacksonville, FL 32216</td>
<td>904.332.6141</td>
</tr>
<tr>
<td></td>
<td>Palm Beach Area Chapter</td>
<td>4360 Northlake Boulevard, Suite 109, Palm Beach Gardens, FL 33410</td>
<td>561.775.9954</td>
</tr>
<tr>
<td></td>
<td>Southern Florida Chapter</td>
<td>2 Olavewood Boulevard, Suite 200, Hollywood, FL 33020</td>
<td>954.744.5300</td>
</tr>
<tr>
<td></td>
<td>Suncoast Chapter</td>
<td>3507 East Frontage Road, Suite 300, Tampa, FL 33607</td>
<td>813.363.6461</td>
</tr>
<tr>
<td>Georgia</td>
<td>Georgia Chapter</td>
<td>3715 Northridge Parkway Building, Suite 400, Suite 300, Atlanta, GA 30317</td>
<td>404.720.7900</td>
</tr>
<tr>
<td>Illinois</td>
<td>Illinois Chapter</td>
<td>651 West Washington Boulevard, Suite 400, Chicago, IL 60661</td>
<td>312.661.7300</td>
</tr>
<tr>
<td></td>
<td>Indiana Chapter</td>
<td>941 East 86th Street, Suite 100, Indianapolis, IN 46240</td>
<td>317.726.2270</td>
</tr>
<tr>
<td>Iowa</td>
<td>Iowa Chapter</td>
<td>8033 University Boulevard, Suite A, Des Moines, IA 50325</td>
<td>515.276.6169 / 800.374.1074</td>
</tr>
<tr>
<td>Kansas</td>
<td>Kansas Chapter</td>
<td>300 North Main, Suite 300, Wichita, KS 67202</td>
<td>316.266.4000</td>
</tr>
<tr>
<td>Kentucky</td>
<td>Kentucky and Southern Indiana Chapter</td>
<td>600 East Main Street, Suite 102, Louisville, KY 40202-1077</td>
<td>502.584.4940</td>
</tr>
<tr>
<td>Maryland</td>
<td>Maryland Chapter</td>
<td>11350 McCormick Road, Executive Plaza II, Suite 100, Hunt Valley, MD 21013</td>
<td>410.891.1999</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>Massachusetts Chapter</td>
<td>9 Erie Drive, Suite 101, Natick, MA 01760</td>
<td>508.810.1300 / 800.688.6752</td>
</tr>
<tr>
<td>Michigan</td>
<td>Michigan Chapter</td>
<td>1421 East Twelve Mile Road, Building A, Madison Heights, MI 48071</td>
<td>248.582.2900</td>
</tr>
<tr>
<td>Minnesota</td>
<td>Minnesota Chapter</td>
<td>8441 Wayzata Boulevard, Suite 340, Twin Cities, MN 55426</td>
<td>763.852.3000</td>
</tr>
<tr>
<td>Missouri</td>
<td>Missouri Chapter</td>
<td>3636 South I-10 Service Road, Suite 304, Mesquite, TX 75150</td>
<td>903.437.0945</td>
</tr>
<tr>
<td>New York</td>
<td>Long Island Chapter</td>
<td>555 Broad Hollow Road, Suite 403, Malverne, NY 11547</td>
<td>631.752.8500</td>
</tr>
<tr>
<td></td>
<td>New York City Chapter</td>
<td>475 Park Avenue South, 8th Floor, New York, NY 10016</td>
<td>212.376.7100</td>
</tr>
<tr>
<td></td>
<td>Upstate New York/Vermont Chapter</td>
<td>5 Computer Drive West, Suite 100, Albany, NY 12205</td>
<td>518.481.3583</td>
</tr>
<tr>
<td></td>
<td>Western New York and Finger Lakes Chapter</td>
<td>403 Maple Road, Amherst, NY 14226, 716.834.2578</td>
<td></td>
</tr>
<tr>
<td>North Carolina</td>
<td>Eastern North Carolina Chapter</td>
<td>401 Harrison Oaks Boulevard, Suite 200, Cary, NC 27513</td>
<td>919.396.7100</td>
</tr>
<tr>
<td></td>
<td>Western North Carolina Chapter</td>
<td>5950 Fairview Road, Suite 250, Charlotte, NC 28210</td>
<td>704.998.5012</td>
</tr>
<tr>
<td>Ohio</td>
<td>Central Ohio Chapter</td>
<td>2225 City Gate Drive, Suite E, Columbus, OH 43219</td>
<td>614.476.7194</td>
</tr>
<tr>
<td></td>
<td>Northern Ohio Chapter</td>
<td>23297 Commerce Park Road, Cleveland, OH 44122, 216.910.1200</td>
<td></td>
</tr>
<tr>
<td>Oklahoma</td>
<td>Oklahoma Chapter</td>
<td>500 North Broadway, Suite 250, Oklahoma City, OK 73102</td>
<td>405.943.8888</td>
</tr>
<tr>
<td>Oregon/SW Washington</td>
<td>Oregon/Southwest Washington Chapter</td>
<td>9320 SW Barbur Boulevard, Suite 140, Portland, OR 97219</td>
<td>503.245.9866</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>Central Pennsylvania Chapter</td>
<td>800 Corporate Circle, Suite 100, Harrisburg, PA 17110</td>
<td>717.652.6520</td>
</tr>
<tr>
<td></td>
<td>Eastern Pennsylvania Chapter</td>
<td>555 North Lane, Suite 3010, Conshohocken, PA 19428</td>
<td>610.238.0360</td>
</tr>
<tr>
<td></td>
<td>Pennsylvania and Virginia/Chesapeake Chapter</td>
<td>River Walk, Corporate Centre, 333 East Carson Street, Suite 441, Pittsburgh, PA 15219</td>
<td>412.395.2873</td>
</tr>
<tr>
<td>Rhode Island</td>
<td>Rhode Island Chapter</td>
<td>1210 Pontiac Avenue, Cranston, RI 02920</td>
<td>401.943.8888</td>
</tr>
<tr>
<td>South Carolina</td>
<td>South Carolina Chapter</td>
<td>107 Westpark Boulevard, Suite 150, Columbia, SC 29210</td>
<td>803.731.4060</td>
</tr>
<tr>
<td>Tennessee</td>
<td>Tennessee Chapter</td>
<td>404 BNA Drive, Suite 102, Nashville, TN 37217</td>
<td>615.331.2980</td>
</tr>
<tr>
<td>Texas</td>
<td>Central Texas Chapter</td>
<td>9211 Waterford Centre Boulevard, Suite 275, Austin, TX 78758</td>
<td>512.495.6610</td>
</tr>
<tr>
<td></td>
<td>North Texas Chapter</td>
<td>8111 LBJ Freeway-Suite 425, Dallas, TX 75231</td>
<td>972.996.5000</td>
</tr>
<tr>
<td></td>
<td>South Texas Chapter</td>
<td>950 Icom Road, Suite 125, San Antonio, TX 78215, 210.377.1915</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Texas Gulf Coast Chapter</td>
<td>5005 Mitchell-Suite 115, Houston, TX 77020, 713.680.5088</td>
<td></td>
</tr>
<tr>
<td>Virginia</td>
<td>Virginia Chapter</td>
<td>5511 Staples Mill Road, Suite 208, Richmond, VA 23228</td>
<td>804.627.0700</td>
</tr>
<tr>
<td>Washington</td>
<td>Washington/Alaska Chapter</td>
<td>5130 Dieder Avenue, North Suite 300, Seattle, WA 98109</td>
<td>206.638.0777</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>Wisconsin Chapter</td>
<td>200 South Executive Drive, Brookfield, WI 53005</td>
<td>262.790.4701</td>
</tr>
<tr>
<td>Canada</td>
<td>Canada Corporate Chapter</td>
<td>80-4 Lansing Square, Toronto, ON M2J 4R9</td>
<td>416.661.9541 / 604-732-2873</td>
</tr>
<tr>
<td>BC/Yukon Region/Vancouver Chapter</td>
<td>1682 West 7th Avenue, Suite 310, Vancouver, BC V6J 5M6</td>
<td>604.732.2873</td>
<td></td>
</tr>
<tr>
<td>Ontario Region/Ashland Area Chapter</td>
<td>480 University Avenue, Suite 1502, Toronto, ON M5G 1V2</td>
<td>416.585.2873</td>
<td></td>
</tr>
<tr>
<td>Prairies Region/Calgary Chapter</td>
<td>110-202 Centre Street S.E., Calgary, AB T2G 5A5</td>
<td>403.263.5300</td>
<td></td>
</tr>
<tr>
<td>Quebec Region/Montreal Chapter</td>
<td>705-1255 University Street, Montreal, QC H3J 3W1</td>
<td>514.875.1000</td>
<td></td>
</tr>
</tbody>
</table>

36
WE NEED YOUR HELP
TO KEEP HELPING OTHERS.
THE LEUKEMIA & LYMPHOMA SOCIETY
IS A NONPROFIT ORGANIZATION
THAT RELIES ON THE GENEROSITY
OF INDIVIDUAL, FOUNDATION
AND CORPORATE CONTRIBUTIONS
TO ADVANCE ITS MISSION.

The Leukemia & Lymphoma Society®
Fighting Blood Cancers

1311 Mamaroneck Avenue • Suite 310 • White Plains, NY 10605 • 914.949.5213 • www.lls.org